Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase-polymerase chain reaction
J.R. Downing; S.A. Shurtleff; M. Zielenska; A.M. Curcio-Brint; F.G. Behm; D.R. Head; J.T. Sandlund; D.D. Weisenburger; A.E. Kossakowska; et al. (Profiled Author: Marc Ladanyi)
The t(2;5)(p23;q35) translocation was initially identified in cases of anaplastic large-cell lymphoma (ALCL) that expressed the Ki-1 (CD30) antigen. We have recently cloned this translocation and shown it to encode a chimeric product consisting of the N-terminal portion of a nonribosomal nucleolar phosphoprotein, nucleophosmin (NPM), from chromosome 5, fused to the kinase domain of a novel transmembrane tyrosine-specific protein kinase, anaplastic lymphoma kinase (ALK), from chromosome 2. To better define the spectrum of lymphomas that contain this translocation, we have analyzed 70 cases of non- Hodgkin's lymphoma (NHL) for expression of the t(2;5)-derived NPM/ALK chimeric message by reverse transcriptase-polymerase chain reaction (RT- PCR). Using a previously described set of oligonucleotide primers, NPM/ALK chimeric transcripts were detected in 21 of 22 cases that contained the t(2;5) by cytogenetic analysis and in 10 of 48 cases that either lacked evidence of the t(2;5) or had unsuccessful cytogenetics. In all but 1 case, the NPM/ALK PCR products were of identical size and sequence, suggesting that the genomic chromosome breaks are clustered in a single intron in both NPM and ALK. The NPM/ALK-expressing cases were not confined to NHLs with anaplastic morphology and included 15 ALCLs, 6 immunoblastic lymphomas, and 10 diffuse large-cell lymphomas. Moreover, only slightly greater than half of the cases with anaplastic morphology and 59% of CD30-expressing cases were NPM/ALK positive. Thus, neither anaplastic morphology nor the expression of CD30 accurately predicted the presence of this molecular genetic subtype of lymphoma.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Seeta R. Chaganti; Weiyi Chen; Nasser Parsa; Kenneth Offit; Diane C. Louie; Riccardo Dalla-Favera; R.S.K. ChagantiGenes Chromosomes and Cancer. 1998;23(4):323-327.
S.A.D. Ebrahim; M. Ladanyi; S.B. Desai; K. Offit; S.C. Jhanwar; D.A. Fillippa; P.H. Lieberman; R.S.K. ChagantiGenes Chromosomes and Cancer. 1990;2(1):27-35.
Lan Lin; Jeannette Y. Lee; Lawrence D. Kaplan; Bruce J. Dezube; Ariela Noy; Susan E. Krown; Alexandra M. Levine; Yanxing Yu; Gary S. Hayward; Richard F. AmbinderJournal of Clinical Oncology. 2009;27(15):2496-2502.
Appears in this Document